{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Peritoneal+%28Metastatic%29+Cancer&page=2", "query": { "condition": "Peritoneal (Metastatic) Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Peritoneal+%28Metastatic%29+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T04:55:25.107Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06756035", "title": "CT-95 in Advanced Cancers Associated With Mesothelin Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelin-Expressing Tumors", "Epithelial Ovarian Cancer", "Malignant Pleural Mesothelioma, Advanced", "Malignant Peritoneal Mesothelioma, Advanced", "Pancreatic Adenocarcinoma Advanced or Metastatic", "Lung Adenocarcinoma Metastatic", "Cholangiocarcinoma Advanced", "Cholangiocarcinoma Non-resectable", "Mesothelin-expressing Advanced Cancers", "Mesothelin-positive Advanced Malignant Solid Tumors", "Colorectal Cancer" ], "interventions": [ { "name": "CT-95", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Context Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2025-03-31", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-11T04:55:25.107Z", "location_count": 8, "location_summary": "Denver, Colorado • Chicago, Illinois • Grand Rapids, Michigan + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06756035" }, { "nct_id": "NCT07277413", "title": "A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NSCLC Adenocarcinoma", "Gastroesophageal Cancer (GC)", "Gastric Adenocarcinoma", "Adenocarcinoma of Esophagus", "Squamous Cell Car. - Esophagus", "Urothelial Carcinoma (UC)", "Bladder Cancer", "Mesothelioma", "Pleural Mesothelioma", "Peritoneal Mesothelioma", "Non-Small Cell Lung Cancer NSCLC", "Pancreatic Cancer", "Biliary Tract Carcinoma" ], "interventions": [ { "name": "IDE892", "type": "DRUG" }, { "name": "IDE397", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDEAYA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2026-03-04", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-06-11T04:55:25.107Z", "location_count": 12, "location_summary": "Orlando, Florida • Omaha, Nebraska • New York, New York + 8 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07277413" }, { "nct_id": "NCT07030283", "title": "Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "NALIRIFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2025-12-31", "completion_date": "2030-07-01", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-06-11T04:55:25.107Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07030283" }, { "nct_id": "NCT02898207", "title": "Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic High Grade Fallopian Tube Serous Adenocarcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Primary Peritoneal Serous Adenocarcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Breast Carcinoma", "Recurrent High Grade Fallopian Tube Serous Adenocarcinoma", "Recurrent High Grade Ovarian Serous Adenocarcinoma", "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma", "Recurrent Triple-Negative Breast Carcinoma", "Refractory Fallopian Tube Serous Adenocarcinoma", "Refractory Ovarian Serous Adenocarcinoma", "Refractory Primary Peritoneal Serous Adenocarcinoma", "Refractory Triple-Negative Breast Carcinoma", "Unresectable High Grade Fallopian Tube Serous Adenocarcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Primary Peritoneal Serous Adenocarcinoma" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Onalespib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2017-05-19", "completion_date": "2022-01-14", "has_results": true, "last_update_posted_date": "2023-04-26", "last_synced_at": "2026-06-11T04:55:25.107Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02898207" }, { "nct_id": "NCT06714617", "title": "Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer Stage III", "HER2-positive Metastatic Breast Cancer", "Unresectable Breast Carcinoma", "Her2-Positive", "HER2 Gene Mutation", "Gastroesophageal-junction Cancer", "Non Small Cell Lung Cancer", "Endometrial Neoplasms", "Peritoneal Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Urothelial Carcinoma Bladder", "Solid Tumor, Adult", "Gastric Cancer" ], "interventions": [ { "name": "BL-M17D1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SystImmune Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-04-10", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-06-11T04:55:25.107Z", "location_count": 9, "location_summary": "Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06714617" }, { "nct_id": "NCT01815359", "title": "ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Appendix Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "Cytoreductive Surgery", "type": "PROCEDURE" }, { "name": "HIPEC with Mitomycin-C", "type": "DRUG" }, { "name": "EPIC with FUDR and Leucovorin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 292, "start_date": "2013-03", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-06-11T04:55:25.107Z", "location_count": 9, "location_summary": "Miami, Florida • St Louis, Missouri • Basking Ridge, New Jersey + 6 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01815359" }, { "nct_id": "NCT00003670", "title": "Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "arzoxifene hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "1998-10", "completion_date": "2001-01", "has_results": false, "last_update_posted_date": "2012-06-07", "last_synced_at": "2026-06-11T04:55:25.107Z", "location_count": 4, "location_summary": "Columbia, Missouri • Chapel Hill, North Carolina • Abington, Pennsylvania + 1 more", "locations": [ { "city": "Columbia", "state": "Missouri" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Abington", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003670" }, { "nct_id": "NCT05802056", "title": "Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage IV Gastric Cancer AJCC v8", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Metastatic Gastric Carcinoma", "Metastatic Malignant Neoplasm in the Peritoneum" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Diagnostic Laparoscopy", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-11-29", "completion_date": "2030-04-15", "has_results": false, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-06-11T04:55:25.107Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05802056" }, { "nct_id": "NCT06016179", "title": "Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Pleural Effusion", "Malignant Ascites" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 12, "start_date": "2024-01-30", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2025-05-22", "last_synced_at": "2026-06-11T04:55:25.107Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06016179" }, { "nct_id": "NCT00402766", "title": "Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2006-08", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-06-11T04:55:25.107Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00402766" } ] }